Advertisement

Your search for lung cancer matches 589 pages

Showing 1 - 50


breast cancer
head and neck cancer
lung cancer

Receptor Tyrosine Kinase AXL May Mediate Nuclear Translocation of EGFR

New research from the University of Wisconsin (UW) Carbone Cancer Center has clarified the mechanisms involved in a common growth pathway implicated in many solid tumor types and could lead to better outcomes for patients with head and neck, lung, and triple-negative breast cancer,...

Lung Cancer

Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Glenwood Goss, MD, of The Ottawa Hospital Cancer Centre, University of Ottawa, and colleagues found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small...

Lung Cancer

Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer

In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...

Lung Cancer

New Treatments for Lung Cancer in 2016

With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...

Lung Cancer

Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer

One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...

Lung Cancer
Cost of Care

A Lung Cancer Specialist Talks About Value in Cancer Care

Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...

Lung Cancer

Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer

On October 24, 2016, pembrolizumab (Keytruda) was approved for use in patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%) as determined by a U.S. Food and Drug Administration...

Issues in Oncology
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Colorectal Cancer

At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints

The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...

Lung Cancer
Skin Cancer

Numerous ESMO Presentations Focused on Anti–PD-1 Therapy in Lung Cancer and Melanoma

The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti–programmed cell death protein 1 (PD-1) antibodies in non–small cell lung cancer and melanoma, where they have clearly changed the treatment paradigm. Here is a roundup of some of those trials,...

Lung Cancer

Studies Confirm Ceritinib’s Benefit in ALK-Positive Patients

For patients with advanced non–small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was...

Lung Cancer

Neoadjuvant Nivolumab Appears Safe and Feasible in Lung Cancer

Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non–small cell lung cancer (NSCLC). The results come from the first report of PD-1 blockade prior to surgery in this tumor, according to Patrick Forde, MD, of...

Lung Cancer

Immunotherapy Clinical Trials Actively Recruiting Patients With Non–Small Cell Lung Cancer

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy as treatment for non–small cell lung cancer (NSCLC). These studies are researching programmed cell death ligand 1 (PD-L1) antibody therapy; hypofractionated...

Lung Cancer

Pembrolizumab as First-Line Therapy in Metastatic NSCLC: Practice-Changing Implications of KEYNOTE-024 Trial

We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival in the second-line setting compared with docetaxel for patients with...

Lung Cancer

Pembrolizumab Improves Outcomes vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC

In the phase III KEYNOTE-024 trial reported in The New England Journal of Medicine by Martin Reck, MD, PhD, of the German Center of Lung Research, Grosshansdorf, and colleagues, pembrolizumab (Keytruda) significantly improved progression-free and overall survival vs platinum-based chemotherapy in...

Lung Cancer

Enrollment Disparity in National Lung Cancer Trials

Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...

Lung Cancer

Modified Indication for Erlotinib in Advanced Non–Small Cell Lung Cancer

On October 18, 2016, the indication for erlotinib (Tarceva) in the treatment of non–small cell lung cancer (NSCLC) was modified to limit use to patients with tumors with specific epidermal growth factor receptor (EGFR) mutations in maintenance or second- or greater-line treatment; these mutations...

Lung Cancer

Atezolizumab in Previously Treated Metastatic NSCLC

On October 18, 2016, the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab (Tecentriq) was approved for the treatment of metastatic non–small cell lung cancer (NSCLC) progressing during or following platinum-containing chemotherapy.1,2 Patients with epidermal growth factor receptor ...

Lung Cancer

FDA Approves Pembrolizumab as First-Line Treatment for PD-L1–Positive Non–Small Cell Lung Cancer

On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) as determined by an FDA-approved test. This is the first...

Lung Cancer

Pembrolizumab, but Not Nivolumab, Improves Outcomes in Front-Line Setting for PD-L1–Positive Advanced NSCLC

Checkpoint inhibitors have revolutionized the treatment of advanced non–small cell lung cancer (NSCLC), but evidence of their benefit was restricted to the second-line setting. However, early-phase trials with both pembrolizumab (Keytruda) and nivolumab (Opdivo) demonstrated favorable results in...

lung cancer
issues in oncology

Multiple Genetic Mutational Signatures Associated With Smoking

Scientists have measured the genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory, and their collaborators ...

Lung Cancer

Pembrolizumab Plus Chemotherapy Improves Outcomes Over Chemotherapy Alone in Advanced NSCLC

Combining immunotherapy with a standard chemotherapy doublet appears to be an attractive option for the front-line treatment of advanced nonsquamous non–small cell lung cancer (NSCLC), according to the results of a phase II study presented at the 2016 European Society for Medical Oncology (ESMO)...

Lung Cancer

Notable Gains in Survival Achieved With Atezolizumab in Non–Small Cell Lung Cancer

The programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) significantly improved overall survival, compared to docetaxel, in previously treated, advanced non–small cell lung cancer (NSCLC), according to preliminary results of the phase III OAK study. The findings are the first...

Lung Cancer
Skin Cancer
Kidney Cancer

Modification of Dosage Regimen for Nivolumab in Renal Cell Carcinoma, Melanoma, and NSCLC

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 13, 2016, the U.S. Food and Drug Administration...

Lung Cancer

Retrospective Studies Confirm Survival Benefit of Stereotactic Body Radiotherapy in Early-Stage NSCLC

Stereotactic body radiation therapy is becoming more widely adopted for the treatment of early-stage non–small cell lung cancer (NSCLC). Along with its increasing uptake, survival has significantly increased over the past decade, according to two large retrospective studies presented at the 58th...

lung cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)

Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)

lung cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial (Spanish Language Version)

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)

lung cancer

Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–small cell lung cancer previously treated with chemotherapy and crizotinib.

lung cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial (French Language Version)

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)

lung cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)

lung cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024

Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)

lung cancer

Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib. (Abstract LBA42)

lung cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Abstract LBA43)

lung cancer

Tony Mok, MD, on NSCLC: Results of the IMPRESS Study

Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive non-small cell lung cancer after progression on first-line gefitinib. (Abstr 1201O)

Lung Cancer

Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)

Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...

Lung Cancer

Phase III Trial Finds No Survival Benefit of Adding Ipilimumab to Etoposide/Platinum in Newly Diagnosed Extensive-Stage SCLC

In a phase III trial (CA184-156) reported in the Journal of Clinical Oncology by Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, and colleagues, the addition of the anti–CTLA-4 (cytotoxic T-lymphocyte–associated protein 4) checkpoint inhibitor ipilimumab (Yervoy) to...

lung cancer
issues in oncology

ASTRO 2016: Intervention Closes Racial Gap and Improves Treatment Rates for Early-Stage Lung Cancer

Enhanced, culturally competent communication with early-stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented by Manning et al at the 58th Annual Meeting of the American Society for Radiation...

lung cancer

Maria Werner-Wasik, MD, on Issues in Lung Toxicity

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)

lung cancer

Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer

Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)

kidney cancer
lung cancer
skin cancer

Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors

A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...

Lung Cancer

FDA Grants Priority Review to Pembrolizumab Supplemental Biologics License Application for First-Line Treatment of Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small cell lung cancer...

Lung Cancer

Lung Cancer Specialist Shares Clinical Pearls for Managing Stage IIIA Non–Small Cell Lung Cancer

Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....

Lung Cancer

Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC

For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...

Lung Cancer

First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC

The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging efficacy and safety findings were reported in the Journal...

kidney cancer
lung cancer
skin cancer

FDA Modifies Dosage Regimen for Nivolumab

On September 13, 2016, the U.S. Food and Drug Administration (FDA) modified the dosage regimen for nivolumab (Opdivo) for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non–small cell lung cancer (NSCLC). The currently approved recommended dosage...

cns cancers
lung cancer

Little Benefit Reported With WBRT in NSCLC Patients With Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy

In a UK-based phase III noninferiority trial (QUARTZ) reported in The Lancet, Mulvenna et al found that use of whole-brain radiotherapy in addition to optimal supportive care including dexamethasone was associated with little additional benefit in non–small cell lung cancer (NSCLC) patients...

Lung Cancer

Phase III Study Launches in Patients With Small Cell Lung Cancer

On August 2, 2016, PharmaMar announced the start of a pivotal phase III ATLANTIS study evaluating the efficacy and safety of ­lurbinectedin (PM1183), a novel synthetic tetrahydroisoquinoline that targets active transcription. The study is evaluating lurbinectedin combined with doxorubicin vs...

kidney cancer
lung cancer
skin cancer

Incidence of PD-1 Inhibitor–Related Pneumonitis in Advanced NSCLC, Renal Cell Carcinoma, and Melanoma

In a systematic review and meta-analysis reported in JAMA Oncology, Nishino et al identified the rates of PD-1 (programmed cell death protein 1) inhibitor–related pneumonitis in patients with advanced non–small cell lung cancer (NSCLC), renal cell carcinoma, and melanoma. Rates were...

Skin Cancer
Lung Cancer

Pembrolizumab for Untreated/Progressive Brain Metastases in Melanoma or NSCLC

Sarah B. Goldberg, MD, of Yale University School of Medicine, and colleagues found that pembrolizumab (Keytruda) was active in untreated or progressive brain metastases in melanoma and non–small cell lung cancer (NSCLC), according to a single-center phase II trial reported in The Lancet Oncology....

Lung Cancer

Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer

Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...

Lung Cancer

Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy

Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...

Advertisement

Advertisement



Advertisement

click me